Show simple item record

dc.contributor.authorLonial, Sen_US
dc.contributor.authorAnderson, K Cen_US
dc.date.accessioned2014-03-11T13:53:24Z
dc.date.issued2014en_US
dc.identifier.citationLonial, S., and K C Anderson. 2014. “Association of response endpoints with survival outcomes in multiple myeloma.” Leukemia 28 (2): 258-268. doi:10.1038/leu.2013.220. http://dx.doi.org/10.1038/leu.2013.220.en
dc.identifier.issn0887-6924en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879838
dc.description.abstractSince the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer. These improvements have afforded more robust analyses of the relationship between response and survival. Generally, these studies have demonstrated that improvements in the quality of response across all stages of treatment are associated with better disease control and longer survival. Thus, achievement of maximal response should be strongly considered, particularly in the frontline setting, but must also be balanced with tolerability, quality of life and patient preferences. In select patients, achievement of a lesser response may be adequate to prolong survival, and attempts to treat these patients to a deeper response may place them at unnecessary risk without significant benefit. Maintenance therapy has been shown to improve the quality of response and disease control and, in some studies, survival. Studies support maintenance therapy for high-risk patients as a standard of care, and there are emerging data supporting maintenance therapy in standard-risk patients to improve progression-free and possibly overall survival. Multidrug regimens combining a proteasome inhibitor and an IMiD have shown exceptional response outcomes with acceptable increases in toxicity in both the frontline and salvage settings, and are becoming a standard treatment approach. Moving forward, the use of immunophenotypic and molecular response criteria will be essential in better understanding the impact of highly active and continuous treatment regimens across myeloma patient populations. Future translational studies will help to develop antimyeloma agents to their fullest potential. The introduction of novel targeted therapies, including the IMiD pomalidomide and the proteasome inhibitors carfilzomib and ixazomib (MLN9708), will provide greater options to individualize treatment and help patients achieve a clinically meaningful response.en
dc.language.isoen_USen
dc.publisherNature Publishing Groupen
dc.relation.isversionofdoi:10.1038/leu.2013.220en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918869/pdf/en
dash.licenseLAAen_US
dc.subjectmyelomaen
dc.subjectdepth of responseen
dc.subjectdurability of responseen
dc.subjectsurvivalen
dc.subjectminimal residual diseaseen
dc.subjectmultidrug treatmenten
dc.titleAssociation of response endpoints with survival outcomes in multiple myelomaen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalLeukemiaen
dc.date.available2014-03-11T13:53:24Z
dc.identifier.doi10.1038/leu.2013.220*


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record